Cancer clinical trials shouldn’t discriminate—but they do

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In 2004, doctors told my husband Mike there was nothing more they could do—the pancreatic cancer he was diagnosed with would soon take his life. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Erin Miller
Development manager, Lazarex Cancer Foundation
Table of Contents

YOU MAY BE INTERESTED IN

Positive high-level results from the POTOMAC phase III trial showed one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer compared to BCG induction and maintenance therapy alone.​
Erin Miller
Development manager, Lazarex Cancer Foundation

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login